The selective PI3Kα inhibitor alpelisib combined with fulvestrant is permitted to treat breast HR‐positive, HER2‐negative breast cancer harboring PIK3CA mutation after an endocrine‐based regimen. The gene discussed is ERBB2; the disease is breast cancer.